- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07278479
Badanie [212Pb]Pb-DOTAM-MAM279 u pacjentów z drobnokomórkowym rakiem płuca i innymi guzami litymi eksprymującymi DLL3
Badanie fazy 1/2a oceniające bezpieczeństwo, tolerancję i skuteczność [212Pb]Pb-DOTAM-MAM279 u pacjentów z drobnokomórkowym rakiem płuca i innymi guzami litymi ekspresjonującymi DLL3
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
This is a phase I/IIa, open-label, multi-center study to evaluate the safety, tolerability, dosimetry, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of [212Pb]Pb-MP0712 in patients with SCLC and other advanced DLL3-expressing solid tumors. The study consists of a dose escalation part, followed by a dose expansion part. Once the recommended radioactive dose(s) [212Pb]Pb-MP0712 for further clinical evaluation are determined, the dose expansion part will further characterize the safety, tolerability, and preliminary anti-tumor activity of [212Pb]Pb-MP0712. The study will enable evaluation of the safety, dosimetry, PK, and imaging properties of [203Pb]Pb-MP0712.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Medical Director MPAG
- Numer telefonu: +41 44 755 77 00
- E-mail: info@molecularpartners.com
Lokalizacje studiów
-
-
Florida
-
Miami, Florida, Stany Zjednoczone, 33136
- Rekrutacyjny
- University of Miami
-
Tampa, Florida, Stany Zjednoczone, 33612
- Rekrutacyjny
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- Rekrutacyjny
- Emory University Hospital
-
Kontakt:
- Ryan Hanula
- Numer telefonu: 404-778-5141
- E-mail: rhanula@emory.edu
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60637
- Rekrutacyjny
- University of Chicago
-
-
Maryland
-
Glen Burnie, Maryland, Stany Zjednoczone, 21061
- Rekrutacyjny
- United Theranostics
-
Kontakt:
- Amanda Huggins
- Numer telefonu: 667-HOPENOW
- E-mail: clinicaltrial@unithera.com
-
-
Nebraska
-
Omaha, Nebraska, Stany Zjednoczone, 68130
- Rekrutacyjny
- Nebraska Cancer Specialists
-
Kontakt:
- Research Director
- Numer telefonu: 402-955-2691
- E-mail: clinicaltrials@nebraskacancer.com
-
-
New Jersey
-
Princeton, New Jersey, Stany Zjednoczone, 08540
- Rekrutacyjny
- United Theranostics
-
Kontakt:
- Amanda Huggins
- Numer telefonu: 667-HOPENOW
- E-mail: clinicaltrial@unithera.com
-
-
Ohio
-
Cleveland, Ohio, Stany Zjednoczone, 44106
- Rekrutacyjny
- University Hospitals Cleveland Medical Center
-
Kontakt:
- Dr A.Dowlati
- Numer telefonu: 216-368-1122
- E-mail: afshin.dowlati@uhhospitals.org
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77030
- Rekrutacyjny
- The University of Texas MD Anderson Cancer Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Key Inclusion Criteria:
-
Age ≥ 18 years old
-
Histologically or cytologically confirmed: I. advanced extensive or limited SCLC or LC NECs of the lung
- SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based therapy and immunotherapy or are not suitable or tolerating the standard of care treatment as second line of systemic therapy, or
- LC NEC of the lung patients with progression or recurrence following at least one prior line of systemic therapy, or II. epNECs with progression or recurrence following at least one prior line of systemic therapy:
- Gastroenteropancreatic NECs (GEPNEC), or
- Cervical NECs, or
- Bladder NECs, or
- other epNECs with previously confirmed DLL3 expression by IHC.
- Patients with prior DLL3-targeted therapy are allowed.
-
For epNECs in Part 1 and Part 2 and SCLC or LC NECs of the lung in Part 2: DLL3-positivity by [203Pb]Pb-DOTAM-MAM279 SPECT/CT
-
Radiographically documented disease progression or recurrence during or after the last line of systemic treatment therapy
-
At least one measurable disease per RECIST v1.1.
-
Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening
-
Adequate blood counts: Hemoglobin ≥9 g/dL; Absolute neutrophil count (ANC) ≥1.5 × 10^9/L; Platelets ≥100 × 10^9/L; White blood cells (WBC) ≥2.5 x 10^9/L;
-
Adequate hepatic function
-
Adequate renal function: Calculated glomerular filtration rate (GFR) >60mL/min (using Cockroft-Gault formula).
-
Patients with known central nervous system (CNS) metastasis will be eligible if they are clinically stable.
Key Exclusion Criteria:
- Uncontrolled intercurrent illness
- Patients who have not had resolution of all clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for grade ≤2 alopecia, or stable grade 2 sensory neuropathy, according to the last CTCAE version).
- Active clinically significant cardiac disease
- Evidence of interstitial lung disease or active, non-infectious pneumonitis.
- History of other malignancy within the past 2 years with exceptions.
Other protocol-defined inclusion/exclusion criteria may apply.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: [203Pb]Pb-DOTAM-MAM279/[212Pb]Pb-DOTAM-MAM279
Patients will receive [203Pb]Pb-DOTAM-MAM279 for Imaging/Dosimetry followed by [212Pb]Pb-DOTAM-MAM279 for treatment |
Radioligand Therapy
Inne nazwy:
Radioligand Imaging Agent
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To assess incidence and severity of safety events following administration of [212Pb]Pb-DOTAM-MAM279
Ramy czasowe: until 5 years after last dose
|
Type, frequency and severity of adverse events (AEs), and serious adverse events (SAEs), Adverse events of special interest (AESI) and Dose Limiting Toxicities (DLT) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) |
until 5 years after last dose
|
|
To assess dose modifications of [212Pb]Pb-DOTAM-MAM279
Ramy czasowe: until 5 years after last dose
|
Frequency and duration of dose changes |
until 5 years after last dose
|
|
To estimate the maximum tolerated dose (MTD) and/or to define the recommended phase 2 dose (RP2D) for SCLC/LCNEC of the lung and epNECs
Ramy czasowe: Phase 1, from start of treatment to end of first cycle (day 1 - 28)
|
Incidence of dose limiting toxicities |
Phase 1, from start of treatment to end of first cycle (day 1 - 28)
|
|
To evaluate the preliminary anti-tumor activity of [212Pb]Pb-DOTAM-MAM279 in the dose expansion part
Ramy czasowe: Phase 2a only; 12 months
|
Objective Response Rate (ORR) in the expansion phase ORR is defined as the percentage of patients with partial response (PR) or complete response (CR) as per RECIST v1.1 |
Phase 2a only; 12 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To assess maximum concentration (Cmax) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
Ramy czasowe: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine maximum concentration (Cmax) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To assess the area under the curve (AUC) from time 0 to the time of the last quantifiable concentration of [203Pb]Pb-DOTAM-MAM279
Ramy czasowe: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine AUC of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To assess half-live(s) (t½) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
Ramy czasowe: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine half-live(s) (t½) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To assess the clearance (CL) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
Ramy czasowe: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine clearance (CL) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To assess the volume of distribution (Vd) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
Ramy czasowe: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine the volume of distribution (Vd) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To quantitatively predict radiation absorbed doses for therapeutic [212Pb]Pb-DOTAM-MAM279 from [203Pb]Pb-DOTAM-MAM279
Ramy czasowe: Phase 1; up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration
|
Estimation of [212Pb]Pb-DOTAM-MAM279 absorbed dose for healthy organs and tumor lesions based on dosimetry analysis of [203Pb]Pb-DOTAM-MAM279 |
Phase 1; up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration
|
|
To assess incidence and severity of safety events following administration of [203Pb]Pb-DOTAM-MAM279
Ramy czasowe: up to 10 days following [203Pb]Pb-DOTAM-MAM279 administration
|
Type, frequency and severity of adverse events (AEs) and serious adverse events (SAEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
up to 10 days following [203Pb]Pb-DOTAM-MAM279 administration
|
|
To evaluate PFS
Ramy czasowe: Phase 2a only; 12 months
|
Progression-Free Survival (PFS) determined as the time from C1D1 to the date of progression, defined as the first documented progression as per RECIST v1.1 or death for any cause |
Phase 2a only; 12 months
|
|
To evaluate DoR
Ramy czasowe: Phase 2a only; 12 months
|
Duration of response (DoR) in patients with a CR or PR from date of first date of response to the date of RECIST 1.1 progression or death |
Phase 2a only; 12 months
|
|
To evaluate DCR
Ramy czasowe: Phase 2a only; 12 months
|
Disease control rate (DCR) defined as the percentage of patients who have achieved CR, PR, or stable disease (SD) |
Phase 2a only; 12 months
|
|
To evaluate OS
Ramy czasowe: Phase 2a only; approx. 5 years
|
Overall survival (OS) defined as the time from C1D1 to death from any cause |
Phase 2a only; approx. 5 years
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Nowotwory według lokalizacji
- Nowotwory
- Choroby Układu Oddechowego
- Nowotwory według typu histologicznego
- Choroby płuc
- Nowotwory gruczołowe i nabłonkowe
- Rak gruczołowy
- Nowotwory Układu Oddechowego
- Nowotwory klatki piersiowej
- Nowotwory płuc
- Rak
- Nowotwory neuroektodermalne
- Nowotwory, komórki rozrodcze i embrionalne
- Nowotwory, tkanka nerwowa
- Rak, Bronchogenny
- Nowotwory oskrzeli
- Guzy neuroendokrynne
- Rak Drobnokomórkowy Płuc
- Rak, neuroendokrynny
Inne numery identyfikacyjne badania
- MP0712-CP101
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .